We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Orf5.5
Orforglipron Research
Mostly mechanism / observational
38 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Orforglipron studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 559 participants.
Based on 38 studies · 10 meta-analyses · 17 RCTs · 15,603 total participants
Confidence
High confidence
By outcome
Blood sugar & glycemic controlLarge HbA1c reductions in type 2 diabetes across phase-2 (up to ~2.1%) and phase-3 (ACHIEVE-1); superior to dapagliflozin and additive to insulin glargine · Weeks to months
Mostly mechanism / observational27 studies
Weight managementAbout 9-15% weight loss in phase-2 obesity by 36 weeks; ATTAIN-1 phase-3 showed ~11.2% mean loss at 72 weeks at 36 mg vs ~2.1% placebo · Months (titrated)
Mostly mechanism / observational20 studies
Safety & adverse effects
Mostly mechanism / observational7 studies
Active research area
38 studies in the last 5 years · Latest meta-analysis: 2026
20232026
1RCTn=3,127 · very large study2025
In plain English: The mean change in body weight from baseline to week 72 was -7.5%... with 6 mg of orforglipron, -8.4%... with 12 mg, and -11.2%... with 36 mg, as compared with -2.1%... with placebo (P<0.001 for all comparisons).
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. · N Engl J Med (2025)
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Mean weight loss -11.2% at 36 mg vs -2.1% placebo; ≥10% loss in 54.6%, ≥15% in 36.0%, ≥20% in 18.4% (36 mg)
Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved vs placebo
In plain English: At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 with the 12-mg dose, -1.48 with the 36-mg dose, and -0.41 with placebo.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. · N Engl J Med (2025)
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
All doses superior to placebo on HbA1c (placebo-adjusted up to -1.07 percentage points); mean HbA1c reached ~6.5-6.7%
In plain English: While gastrointestinal tolerability remains a clinically important limitation requiring mitigation strategies, orforglipron represents a promising oral therapeutic option for comprehensive obesity and metabolic management.
Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, Iftikhar S, Saddique MN, Alfalh W, Omar RMB, Abu Dawood H. · Endocrinology, diabetes & metabolism (2025)
Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models.
Orforglipron demonstrated dose-dependent reductions in body weight from 2.48% at 3 mg to 9.8% at 45 mg, BMI from 0.89 to 3.62 kg/m 2 , waist circumference from 1.57 to 6.9 cm, and HbA1c from 0.76% to 1.04% compared with placebo.
Favourable lipid changes included reductions in total cholesterol (MD: -4.51% [95% CI: -6.91 to -2.11]), LDL-C (MD: -5.34% [95% CI: -7.10 to -3.58]), and triglycerides (MD: -10.07% [95% CI: -12.33 to -7.80]), with increased HDL-C (MD: 2.94% [95% CI: 1.38 to 4.49]).
In plain English: Change from baseline in mean HbA1c was -1.23%, -1.50%, and -1.56% with orforglipron 3 mg, 12 mg, and 36 mg, respectively, versus -0.81% with dapagliflozin 10 mg.
Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. · Lancet (2026)
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
All orforglipron doses non-inferior and statistically superior to dapagliflozin on HbA1c (treatment differences -0.42% to -0.75%; all p<0.0001)
Mild-to-moderate GI events in 46-54% of orforglipron groups vs 12% with dapagliflozin
In plain English: TSA indicates conclusions for weight, BMI, and SBP are robust; longer-term comparative trials should refine DBP and safety signals.
Jamal A, Khan S, Qadri M, Shah A, Iftikhar H, Fatima E, Ahmad M, Sikandar M, Jawed I, Muneeb M, Mohmand MS, Bacha Z, Khan BW, Jamal T, Khalid AA, Khan MI, Zulkaif M. · Acta diabetologica (2026)
METHODS: Following PRISMA 2020, randomized controlled trials comparing orforglipron with placebo were combined using random-effects meta-analysis to determine mean differences (MD) or risk ratios (RR) with 95% confidence intervals.
Fasting plasma glucose decreased significantly overall (MD − 25.77 mg/dL, 95% CI − 58.70 to − 7.18; very high heterogeneity; dose-response evident).
Diastolic blood pressure was neutral (primary MD − 0.32 mmHg, 95% CI − 2.36 to 1.71; sensitivity MD + 0.68 mmHg, 95% CI − 0.02 to 1.39).
In plain English: At week 40, the mean changes from baseline in HbA1c were -1.58%, -1.88%, and -1.82% with orforglipron 3 mg, 12 mg, and 36 mg once daily, respectively, vs -0.79% with placebo.
Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. · JAMA (2026)
Phase-3 double-blind RCT (n=546) of orforglipron 3/12/36 mg vs placebo added to titrated insulin glargine in type 2 diabetes over 40 weeks
Each dose superior to placebo on HbA1c (placebo-adjusted -0.78% to -1.08%; P<.001)
Mean body-weight change -2.6% to -5.4% vs +0.2% placebo